In the treatment of myeloproliferative neoplasms (MPNs), 1 interferon agent is FDA approved in the United States. Ropeginterferon alfa-2b-njft (Besremi) is indicated for adults with polycythemia vera (PV), but as research continues to support the use of these agents, oncologists have more questions.
To better understand the underlying mechanisms of action associated with interferons, as well as efficacy, safety, and mechanism of resistance, the MPN Research Foundation (MPNRF) launched a 3-year global initiative.
"It is unusual that we have been effectively using interferon for the treatment of MPNs for more than 30 years without fully understanding how it works," said Richard T. Silver, MD, in a press release about the initiative. "That is why the MPNRF's Interferon Initiative is so important. Interferon appears to uniquely affect the MPN stem cells and has other valuable attributes.
In an interview with Targeted Oncology, Silver, professor emeritus of Medicineat Weill Cornell Medicine, discussed the role of interferon in the treatment of MPNs as well as the importance of the 3-year global MPN initiative being conducted by the MPNRF.
TARGETED ONCOLOGY: Can you discuss which patients benefit from recombinant IFN alpha. What agents are showing promise right now?
Silver: Interferon can be effective in a number of hematologic disease but currently, its primarily used to treat myeloproliferative neoplasms. It was first used to chronic myeloid leukemia [CML] before we had very specific treatment for it. I happen to be very interested in chronic myeloid leukemia, But now, we have much better therapy than interferon, because of the similar for CML because of the similarities of CML to other disease is of the myeloproliferative group.
In 1988, I had the idea of using it in PV and some investigators in Austria have used interferon to treat essential thrombocytopenia [ET]. So, of the 3 MPNs, interferon is most commonly used in PV because many patients with ET do not require therapy at all, when they do interferon is very effective.
We and others have evaluated interferon in very myelofibrosis and find it to be effective in about 80% of cases. Overall, Interferon is more was effective PV because it's been shown that it affects the PV stem cell leading to its exhaustion.
Resistance and intolerance to interferons has been shown. Can you explain how common this is?
Most patients with PV and ET, develop intolerance rather than resistance to interferons, and mostly, it's in the form of peripheral neuralgia. It can be autoimmune disease, and sometimes people get thinking disorders or depressed on interferon. Sometimes they develop liver abnormalities.
It's not a benign drug. If you look at the total of patients who become intolerant to interferon, it's about 15% to 20%. When the drug is used properly, that is to say we're using low doses of interferon, it's about the same number of patients in our series of 470 patients with PV who have developed intolerance to hydroxyurea, which is a commonly used drug in PV treatment. So, all these drugs have side effects, which must be evaluated very carefully.
Resistance to interferon is a very complex issue. Presumably, there are biologic effects in the stem cells that occur that make the stem cell not responsive to interferon. That is being worked on now in the research setting. But we don't know why some patients develop resistance per se to interferon, but that is not as common as intolerance.
Can you talk about the key goals of the 3-Year Global MPN Interferon Initiative?
The Myeloproliferative Neoplasm Research Foundation thats very active in raising funds for research around this disease. They organized an initiative to determine how interferon works or what is the mechanism of action accounting for success. It should be noted parenthetically that interferon was first used in viral diseases, and particularly in hepatitis. Its effect rheumatologically and its use in hematologic disease is really a secondary manifestation of its broad physiologic potential.
To determine how interferon works, a combination of laboratory studies were conducted in 4 different laboratories around the world. The goal was to determining the effectiveness and reason why interferon works in hematological disorders. Based on mouse models, they have demonstrated that interferon is effective, because it affects PV stem cell, and probably is most active in affecting the megakaryocytic stem cell, which is sort of the mother cell of all stem cells. There are other proteins that affect this phenomenon, and these were part of the research that was generated by the MPN Research Foundation.
There are many unanswered questions and many detailed questions that need to be answered before we really have a full understanding of how this drug works hematologically. But, I should also note that many drugs have been used therapeutically before we could really understand the basis for its use. The best example is penicillin. You know, the observation that penicillin was an antibacterial agent was made long before the basis for understanding why it was effective. So, this is very encouraging. At Weill Cornell, where I have the privilege of being a professor, we have just completed a retrospective study of 470 patients who have been treated with phlebotomy only or hydroxyurea or interferon. The study has demonstrated that patients treated with interferon have a much better survival than those treated with hydroxyurea and that hydroxyurea is superior to phlebotomy.
What is your key takeaway from the report published around this initiative?
I think the all the laboratory investigators would agree that we have ways to go before we fully understand the mechanism action of interferon and why it works is most effective, as I said, PV and ET. It works in early phases of myelofibrosis. When myelofibrosis for example, becomes advanced in the bone marrow, it becomes very sclerotic or fibrotic, interferon is not effective. So, there are many questions to be answered. This is the beginning and like all research, when you conduct research, it often opens more questions that are answered. And I think this has been true in this MPN Research Foundation. As I said, I think the most important aspect of this has been to focus the effect of interferon on the MPN stem cell and show that is, in fact, very active on that cell.
What interferon research has been most impressive for the treatment of MPNs?
Ropeginterferon alfa-2b is one that has very long action. That is to say that you can give an injection on day 1 and you wont have to give another injection for another 2 to 4 weeks. This agent has just been FDA approved for the treatment of polycythemia vera in the United States. It was already approved in Europe, so there will be more and more patients being treated with interferon soon.
In your expert opinion, how should interferon be used in the clinical setting? What does the future look like for these agents?
Our goal in using interferon in hematologic malignancies is obviously to keep the patients with a very good quality of life, so they can maintain their professional, social, and family lives with minimal adverse events. That's our goal. And I think we can achieve it with these new forms of interferons. So, I'm very positive.
3-Year Global MPN interferon initiative report released by MPN Research Foundation. News release. MPN Research Foundation. November 1,,2021. Accessed November 23, 2021. https://bit.ly/3DLkeW5
Read more here:
- Mayo Clinic Q and A: Stem cell therapy for arthritis ... - November 29th, 2021
- FDA Warns About Stem Cell Therapies | FDA - November 29th, 2021
- A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked. - The New York Times - November 29th, 2021
- Cell Therapy Markets, 2030 - ResearchAndMarkets.com - Business Wire - November 29th, 2021
- Neuroplast secures 10 million in funding to boost clinical development of stem cell therapy for traumatic spinal cord injuries - Spinal News... - November 29th, 2021
- Innovating Reversible Cell Therapies With RNA - Technology Networks - November 29th, 2021
- US Stem Cell Therapy Market size and analysis by leading manufacturers, application and types 2021-2027 Energy Siren - Energy Siren - November 29th, 2021
- InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body - Galveston County Daily... - November 29th, 2021
- Susanna Park inducted as holder of Roth Endowed Chair for Discovery, Education and Patient Care - UC Davis Health - November 29th, 2021
- Covid vaccine: Stem cell transplant patients who must be completely re-vaccinated struggling to book jabs - iNews - November 29th, 2021
- Immunomic Therapeutics Announces Collaboration With iOncologi - BioSpace - November 29th, 2021
- An Against-the-Odds Cancer Story Can Be Yours - Curetoday.com - November 29th, 2021
- Calls for stem cell donation to change in Australia to reduce reliance on overseas donors - ABC News - November 29th, 2021
- Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma - OncLive - September 5th, 2021
- Cell Therapy Manufacturing Market | Exclusive Report on the Latest Market Trends and Development - PharmiWeb.com - September 5th, 2021
- MD Anderson Now to Offer Solution for Cellular Therapy Toxicities - Targeted Oncology - September 5th, 2021
- NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network - September 5th, 2021
- BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem Program - GuruFocus.com - September 5th, 2021
- Jury awards North Texas doctor $7.8 million in lawsuit over his partner locking him out - The Dallas Morning News - September 5th, 2021
- Iomab-B Shows Early Promise Versus Standard Therapy in Elderly R/R AML - Targeted Oncology - September 5th, 2021
- Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas - OncLive - September 5th, 2021
- MD Anderson and Bellicum Announce Additional License Agreement for Use of CaspaCIDe Safety Switch - Newswise - September 5th, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market by Sales, Revenue, Price and Gross Margin (2021-2027) UNLV The Rebel Yell - UNLV The Rebel Yell - September 5th, 2021
- Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk - February 7th, 2021
- FDA Green Lights Trials of New Type 1 Diabetes Stem Cell Therapy - A Sweet Life - February 7th, 2021
- Breakthrough stem cell therapy may reverse life-threatening conditions in dogs - Study Finds - February 7th, 2021
- Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer - OncLive - February 7th, 2021
- Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,... - February 7th, 2021
- Westin Evaluates Management of DLBCL With CAR T-Cell Therapy - Targeted Oncology - February 7th, 2021
- Stem cells' efficacy confirmed in treating ototoxic hearing loss - Korea Biomedical Review - February 7th, 2021
- Stem cell therapy treatment introduced in Pakistan - The Nation - February 7th, 2021
- Stem Cell Therapy Market Information, Figures and Analytical Insights 2020 2026 - The Courier - February 7th, 2021
- Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell... - February 1st, 2021
- ProgenCell - Stem Cell Therapies offers an updated Stem Cell Therapy for Anti Aging Protocol - PR Web - February 1st, 2021
- Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |... - February 1st, 2021
- Stem Cell Recruitment Therapy Registration Awarded by U.S. Patent & Trademark Office for Russell Health - MDJOnline.com - February 1st, 2021
- Cell and Gene Therapy Firms Gear up to Revolutionize Manufacturing - Labiotech.eu - February 1st, 2021
- Animal Stem Cell Therapy Consumption Market Report By Application, Type, Top Companies, Growth, Regional Outlook, and Forecast to 2027 Murphy's... - February 1st, 2021
- Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes... - February 1st, 2021
- Dancing on Ice's Colin Jackson to get stem cell op as he's got 'knees of 85-year-old' - Irish Mirror - February 1st, 2021
- Advanced Pancreatic Cancer Pipeline Therapeutics and Analysis, 2021 - GlobeNewswire - February 1st, 2021
- ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners -... - January 30th, 2021
- Cell Therapy Market 2020 Industry Size, Share, Segmentation, Comprehensive Analysis and Forecast by 2025 KSU | The Sentinel Newspaper - KSU | The... - January 30th, 2021
- Stem Cell Therapy Market 2021 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2026 NeighborWebSJ - NeighborWebSJ - January 30th, 2021
- Researchers use patients' cells to test gene therapy for rare eye disease - National Institutes of Health - January 30th, 2021
- Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer - PRNewswire - January 30th, 2021
- Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction - Cath Lab... - January 30th, 2021
- Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19 - PRNewswire - January 30th, 2021
- Protein identified that may help treat Parkinsons disease - Medical News Today - January 30th, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium - GlobeNewswire - January 30th, 2021
- Comprehensive Report on Animal Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | ANIMAL CELL THERAPIES,... - December 22nd, 2020
- I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire - December 22nd, 2020
- Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - PRNewswire - December 22nd, 2020
- Glycostem and Ghent University sign license agreement on NK cell therapy technology - PRNewswire - December 22nd, 2020
- Stem Cell Therapy Market to See Massive Growth by 2026 Osiris Therapeutics, NuVasive - Farming Sector - December 22nd, 2020
- Medicine by Design symposium highlights importance of convergence in regenerative medicine and human health - News@UofT - December 22nd, 2020
- Global NK Cell Therapy and Stem Cell Therapy Market: Development, Current Analysis and Estimated Forecast to 2025 - The Courier - December 22nd, 2020
- ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline -... - December 22nd, 2020
- New Combination Therapy Tested By Children's May Offer Hope For Leukemia Patients - WVXU - December 22nd, 2020
- Ashley Cain says over 80,000 people registered for stem cell donation in 48 hours after appeal to save baby - The Sun - December 22nd, 2020
- Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors - Business Wire - December 7th, 2020
- New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies - Newswise - December 7th, 2020
- ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma - Cancer Network - December 7th, 2020
- Stem cell therapy in coronavirus disease 2019: current evidence and future potential - DocWire News - December 7th, 2020
- Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting... - December 7th, 2020
- Treatment to restore vision by injecting stem cells into the eye could help people with damaged eyesight - iNews - December 7th, 2020
- Bayer creates cell and gene therapy platform to support partners - FierceBiotech - December 7th, 2020
- Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Cheshire Media - December 7th, 2020
- ASH Goes Remote as CAR T-Cell Therapy Competition Heats Up - AJMC.com Managed Markets Network - December 7th, 2020
- Hematologist Discusses the Impact a Myeloma CAR T-Cell Approval Would Have on the Treatment Landscape - DocWire News - December 7th, 2020
- Cilta-Cel CAR T-cell Therapy Impresses With High ORR in R/R Multiple Myeloma - Targeted Oncology - December 7th, 2020
- Are stable producer cells the future of viral vector manufacturing and when will allogeneic cell therapy take hold? - BioPharma-Reporter.com - December 7th, 2020
- Global Stem Cell Therapy Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2027 - The Haitian-Caribbean News Network - December 7th, 2020
- Not All Patients With Relapsed DLBCL Referred for CAR T in Community Setting - Targeted Oncology - December 7th, 2020
- CRISPR and another genetic strategy fix cell defects in two common blood disorders - Science Magazine - December 7th, 2020
- Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Cheshire Media - December 7th, 2020
- UCLA receives $7.3 million grant to build state-of-the-art facility for developing gene, cell therapies - UCLA Newsroom - December 7th, 2020
- Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition - GlobeNewswire - December 7th, 2020
- Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma - Curetoday.com - December 7th, 2020
- New Drug Could Improve Effectiveness of Stem Cell Therapy - Pain News Network - December 4th, 2020